Divestiture of Japan business venture (Teva-Takeda) On December 5, 2024, Teva announced agreement to sell its Japan business venture (51% stake in Teva-Takeda) to JKI Co. Ltd. for completion by April 1, 2025. Generic and legacy products. Classified as held for sale at year-end 2024.
▾ expand
Intent to divest API business announced On January 31, 2024, Teva announced intent to divest its API business (R&D, manufacturing and commercial activities) through a sale, in alignment with Pivot to Growth strategy. Classified as held for sale at year-end 2024. Recorded $1,280M goodwill impairment and $275M impairment on classification as held for sale.
▾ expand
Science-Based Targets validated for GHG reduction Teva references validated Science-Based Targets for GHG reductions. Sustainability-linked senior notes include performance targets on absolute greenhouse gas emissions reduction and improving access to medicines in low- and middle-income countries.
▾ expand
Sustainability-linked notes tied to access to medicines Teva has issued sustainability-linked senior notes with targets that include improving access to medicines in low- and middle-income countries and reducing GHG emissions. Failure to achieve targets results in interest rate step-ups of 0.10%-0.375% or one-time premium payments.
▾ expand
CSRD reporting obligation starts 2026 Teva expects to first have to disclose pursuant to EU's Corporate Sustainability Reporting Directive (CSRD) in accordance with European Sustainability Reporting Standards (ESRS) in 2026, including double materiality assessments.
▾ expand
Canada moved from North America to International Markets segment Effective January 1, 2024, Canada is reported as part of the International Markets segment and the North America segment was renamed United States segment. Prior periods were recast.
▾ expand
Primary: EHS management system and climate change mitigation Teva continued implementation of its global EHS management system in 2024 across all countries of operation, with proactive compliance evaluation, EHS leading indicators, and continued promotion of a climate change mitigation and adaptation strategy according to international standards. Water management is being addressed with a scarcity-focused approach to conservation.
▾ expand
Dependent: Supplier audit and supply chain management Teva implemented a supplier audit program to ensure suppliers meet quality and operational standards. The Company sources APIs from its own facilities plus suppliers in Europe, Asia and the Americas, and continues to strengthen its third-party operations unit to meet cost, supply security and quality targets sustainably.
▾ expand
Dependent: Pharmaceutical pollutants — Urban Wastewater Treatment Directive In November 2024, the EU adopted revisions to the Urban Wastewater Treatment Directive requiring pharmaceutical companies to pay for a majority of the costs to remove micropollutants from wastewater. This represents a new product stewardship cost lever extending Teva's environmental responsibility downstream into water treatment infrastructure.
▾ expand
Sale of Japan business venture to JKI/J-Will Partners On December 5, 2024, Teva announced agreement with JKI Co. Ltd. to sell Teva-Takeda generics/legacy business venture in Japan. Expected closing April 1, 2025. Resulted in ~$690M expected loss including FX translation adjustments.
▾ expand
see 8 more events →